Tags

Type your tag names separated by a space and hit enter

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity.
J Exp Med. 2005 Nov 07; 202(9):1159-62.JE

Abstract

Induction of selective, autoantigen-specific tolerance is the "holy grail" for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12-16, 2005, in Boston, MA, a Kirin-sponsored "Ideashop" was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies.

Authors+Show Affiliations

La Jolla Institute for Allergy and Immunology, San Diego, CA 92109, USA. Matthias@liai.orgNo affiliation info available

Pub Type(s)

Congress

Language

eng

PubMed ID

16275758

Citation

von Herrath, Matthias G., and Gerald T. Nepom. "Lost in Translation: Barriers to Implementing Clinical Immunotherapeutics for Autoimmunity." The Journal of Experimental Medicine, vol. 202, no. 9, 2005, pp. 1159-62.
von Herrath MG, Nepom GT. Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med. 2005;202(9):1159-62.
von Herrath, M. G., & Nepom, G. T. (2005). Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. The Journal of Experimental Medicine, 202(9), 1159-62.
von Herrath MG, Nepom GT. Lost in Translation: Barriers to Implementing Clinical Immunotherapeutics for Autoimmunity. J Exp Med. 2005 Nov 7;202(9):1159-62. PubMed PMID: 16275758.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. AU - von Herrath,Matthias G, AU - Nepom,Gerald T, PY - 2005/11/9/pubmed PY - 2006/1/5/medline PY - 2005/11/9/entrez SP - 1159 EP - 62 JF - The Journal of experimental medicine JO - J Exp Med VL - 202 IS - 9 N2 - Induction of selective, autoantigen-specific tolerance is the "holy grail" for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12-16, 2005, in Boston, MA, a Kirin-sponsored "Ideashop" was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies. SN - 0022-1007 UR - https://www.unboundmedicine.com/medline/citation/16275758/Lost_in_translation:_barriers_to_implementing_clinical_immunotherapeutics_for_autoimmunity_ L2 - https://rupress.org/jem/article-lookup/doi/10.1084/jem.20051224 DB - PRIME DP - Unbound Medicine ER -